- Home
- BOWN vs DBVT Comparison
BOWN vs DBVT Comparison
Compare BOWN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWN
- DBVT
- Stock Information
- Founded
- BOWN 2023
- DBVT 2002
- Country
- BOWN United States
- DBVT France
- Employees
- BOWN N/A
- DBVT N/A
- Industry
- BOWN
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOWN
- DBVT Health Care
- Exchange
- BOWN Nasdaq
- DBVT Nasdaq
- Market Cap
- BOWN 100.3M
- DBVT 102.0M
- IPO Year
- BOWN 2023
- DBVT N/A
- Fundamental
- Price
- BOWN $6.84
- DBVT $4.52
- Analyst Decision
- BOWN
- DBVT Strong Buy
- Analyst Count
- BOWN 0
- DBVT 2
- Target Price
- BOWN N/A
- DBVT $22.50
- AVG Volume (30 Days)
- BOWN 37.6K
- DBVT 141.6K
- Earning Date
- BOWN 01-01-0001
- DBVT 03-06-2025
- Dividend Yield
- BOWN N/A
- DBVT N/A
- EPS Growth
- BOWN N/A
- DBVT N/A
- EPS
- BOWN 0.39
- DBVT N/A
- Revenue
- BOWN N/A
- DBVT $12,515,000.00
- Revenue This Year
- BOWN N/A
- DBVT N/A
- Revenue Next Year
- BOWN N/A
- DBVT $2,860.00
- P/E Ratio
- BOWN $18.97
- DBVT N/A
- Revenue Growth
- BOWN N/A
- DBVT 125.54
- 52 Week Low
- BOWN $5.84
- DBVT $0.44
- 52 Week High
- BOWN $11.00
- DBVT $5.42
- Technical
- Relative Strength Index (RSI)
- BOWN 20.33
- DBVT 62.08
- Support Level
- BOWN $5.84
- DBVT $4.47
- Resistance Level
- BOWN $7.90
- DBVT $5.15
- Average True Range (ATR)
- BOWN 1.04
- DBVT 0.41
- MACD
- BOWN -0.42
- DBVT 0.03
- Stochastic Oscillator
- BOWN 19.38
- DBVT 62.96
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.